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We previously showed that inhibition of repeated electroconvulsive shock (ECS)-induced seizures 
through 7-day administration of anti-epileptic drugs suppressed the impairment of spontaneous alter-
nation behavior in the Y-maze test in rats.  To clarify the precise mechanism(s),  we investigated the 
eﬀect of valproate on such impairment and examined the levels of brain-derived neurotrophic factor 
(BDNF) and c-Fos protein in the prefrontal cortex and the hippocampus 24h after the last administra-
tion of ECS.  Seven-day intraperitoneal (i.p.) administration of valproate (400mg/kg) suppressed the 
impairment of spontaneous alternation behavior.  Repeated ECS increased the BDNF protein levels in 
the hippocampus and prefrontal cortex in the presence or absence of valproate,  indicating that the 
increase in BDNF protein levels resulted from electrical stimulation.  c-Fos protein levels were signiﬁ-
cantly decreased in the hippocampal dentate gyrus after repeated ECS,  but valproate had no signiﬁ-
cant eﬀect on decreased c-Fos protein levels.  Valproate＋ECS signiﬁcantly increased the c-Fos protein 
levels of the prefrontal cortex compared with the ECS group.  These ﬁndings suggest that the inhibi-
tory eﬀect of valproate on repeated ECS-induced impairment of spontaneous alternation behavior may 
be linked to the prefrontal cortex.
Key words: electroconvulsive shock-induced seizure,  spontaneous alternation behavior,  valproate,  brain-
derived neurotrophic factor,  c-Fos
pilepsy is the most common neurologic disorder 
of the brain.  It is characterized by recurrent 
seizures resulting from uncontrolled excess activity of 
a part or all of the central nervous system.  Recurrent 
seizures frequently induce psychiatric disorders,  
including cognitive deﬁcits,  behavioral abnormalities 
and emotional impairment [1,  2].
　 In studies using experimental animals,  we have 
shown that repeated electroconvulsive shock (ECS) 
decreased spontaneous alternation behavior in the 
Y-maze test (which assesses short-term memory) and 
increased the locomotor activity of rats in an open-
ﬁeld test [3].  Furthermore,  inhibition of repeated 
ECS-induced seizures by pretreatment with the anti-
epileptic drugs phenytoin (120mg/kg,  i.p.) and val-
proate (400mg/kg,  i.p.) abolished these behavioral 
impairments.  These ﬁndings indicate that the inhibi-
tion of ECS-induced seizures suppresses the impair-
ment of spontaneous alternation and the development 
of locomotor hyperactivity.  Several investigators have 
shown that repeated administration of ECS aﬀects the 
dopaminergic system and that this eﬀect is related to 
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locomotor hyperactivity induced by repeated adminis-
tration of ECS in rats and mice [4-6].  However,  
little is known about the mechanism of the deﬁcit of 
spontaneous alternation induced by repeated ECS.
　 The hippocampus [7] and prefrontal cortex [8] 
have been shown to play important parts in learning 
and memory.  Brain-derived neurotrophic factor 
(BDNF),  which is a member of the neurotrophin fam-
ily,  may have an important role in the brain.  Studies 
have reported that ECS administration increases the 
level of BDNF mRNA [4-6] and BDNF protein in 
rats [6,  9,  10].  In this study,  to clarify the detailed 
mechanisms for the protective eﬀect of valproate,  we 
investigated the eﬀect of valproate (250-500mg/kg 
(i.p.)) on the impairment of spontaneous alternation 
behavior in the Y-maze test and locomotor hyperactiv-
ity in the open-ﬁeld test induced by repeated adminis-
tration of ECS in rats.  We then investigated whether 
cerebral BDNF is associated with the inhibitory eﬀect 
of valproate on behavioral impairments.  It is well 
known that c-Fos (the protein product of the immedi-
ate early gene c-fos) is rapidly induced by various 
stimuli and is used widely as a marker of neuronal 
activation [11].  To analyze the site of action of val-
proate in the brain,  c-Fos protein levels were exam-
ined after repeated administration of ECS and val-
proate.
Materials and Methods
　 Approval of the study protocol. Animal 
experiments were carried out in compliance with the 
Guidelines for Animal Experimentation.  The study 
protocol was approved by the Committee of Animal 
Experimentation of Ehime University School of 
Medicine (Ehime,  Japan).
　 Animals. Male Wistar rats (age,  6 weeks) were 
obtained from Charles River Japan,  Incorporated 
(Yokohama,  Japan).  Rats were housed 2 per cage 
(42cm×26cm×15cm) at 24±2℃ with a 12-h light 
period (7am to 7pm).  Food and water were available 
ad libitum.
　 Drugs. Sodium valproate was purchased from 
Wako Pure Chemical Industries,  Limited (Osaka,  
Japan).  Valproate was dissolved in physiological 
saline (0.9ｵ sodium chloride).  Drugs were injected at 
a volume of 1ml/kg body weight.
　 ECS-Induced seizures. ECS (100V,  50mA,  
60Hz,  0.2 sec) was administered via corneal elec-
trodes once daily for 7 days.  Rats that received ECS 
exhibited generalized tonic-clonic seizures lasting 
～5-10 sec.  Sham rats in the control group were 
handled and treated in a similar manner to the ECS 
group except for electroshock application.
　 Spontaneous alternation behavior in the 
Y-maze test. We examined continuous spontaneous 
alternation behavior using the Y-maze apparatus.  The 
Y-maze apparatus was made of black plastic with three 
arms (40cm×15cm×35cm) extending from a central 
platform at 120°.  Each rat was placed at the end of 
one arm and allowed to move freely through the maze 
during a session lasting 8min.  Arm entry was deﬁned 
as the entry of 4 paws into one arm.  The sequence of 
arm entries was recorded visually.  Alternation was 
deﬁned as multiple entries into the 3 arms (A,  B or C) 
on overlapping triplet sets.  The percentage of sponta-
neous alternation was calculated as the ratio of the 
actual-to-possible alternations (deﬁned as the total 
number of arm entries minus 2),  multiplied by 100: as 
shown in the following equation:
Alternation (ｵ)＝[(number of alternations)/(total 
arm entries－2)]×100
　 Locomotor activity in the open-ﬁeld test.
Rats were individually placed in an acrylic apparatus 
(69cm×28cm) with a gray ﬂoor divided into 19 
squares.  Locomotor activity (deﬁned as grid line 
crossings by all 4 paws) was measured during an 8-min 
period by a digital video camera.
　 Tissue preparation and measurement of 
BDNF protein by enzyme-linked immunosorbent 
assay (ELISA). Rats were killed by decapitation 
24h after the last administration of ECS.  Brains 
were quickly removed and dissected on ice into the 
hippocampus and prefrontal cortex.  Samples were 
frozen at 80℃ before homogenization.  Sections were 
homogenized in lysis buﬀer (137mM NaCl,  20mM 
Tris,  1ｵ NP40,  10ｵ glycerol,  1mM phenylmethyl-
sulfonyl ﬂuoride,  10µg/ml aprotinin,  1µg/ml leupep-
tin,  0.5mM sodium vanadate).  Homogenates were 
centrifuged at 10,000×g for 20min.  The superna-
tants were collected and processed for quantiﬁcation 
of total free BDNF with a BDNF Emax Immuno 
Assay system kit (Promega,  Madison,  WI,  USA).  
ELISAs were carried out using the BDNF Emax 
Immuno Assay System kit according to the manufac-
turerʼs instructions [12].  Nunc Maxisorp 96-well 
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immunoplates were coated with 100µl/well of anti-
BDNF monoclonal antibody (mAb) and incubated 
overnight at 4℃.  Plates were incubated in a block and 
sample buﬀer at room temperature for 1h.  Samples 
were then added to coated wells (100µl) and shaken 
for 2h at room temperature.  The antigen was then 
incubated with an anti-human BDNF polyclonal anti-
body (pAb) for 2h at room temperature with shaking,  
followed by incubation with an anti-IgY antibody con-
jugated to horseradish peroxidase (HP) for 1h at 
room temperature.  Finally,  plates were incubated 
with tetramethylbenzidine solution for 15min,  and 
1M hydrochloride acid was added to the wells.  The 
colorimetric reaction product was measured at 450nm.  
Standard curves were plotted for each plate.  BDNF 
concentrations were determined from the regression 
line for the BDNF standard from 7.8pg/ml to 500pg/
ml for each plate.
　 Immunohistochemistry of c-Fos. Rats were 
acclimated to handling every day for 7 days.  The 
number of rats in each group was 3-4.  Rats were 
deeply anesthetized with sodium pentobarbital.  They 
were perfused transcardially with 200ml of 0.9ｵ 
sodium chloride followed by 300ml of 4ｵ paraform-
aldehyde in 0.1M phosphate buﬀer (pH7.4).  The 
brains were removed and post-ﬁxed in the same ﬁxa-
tive.  Coronal slices (40µm) were cut consecutively 
through the target brain regions with a vibrating 
microtome.  The immunohistochemistry of c-Fos was 
determined as described by Hamamura et al.  [13].  
Sections from diﬀerent treatment groups were pro-
cessed in parallel to minimize the variations in immu-
nohistochemical labeling.  Free-ﬂoating sections were 
rinsed in 0.05M phosphate-buﬀered saline (PBS;  
pH7.4).  They were then incubated with 0.6ｵ hydro-
gen peroxide in PBS to remove endogenous peroxidase 
activity.  After rinsing again in PBS,  sections were 
incubated with primary antibody (1 : 3000 dilution in 
PBS containing 0.3ｵ Triton X-100,  0.05ｵ sodium 
azide and 2ｵ normal goat serum) for 72h at 4℃.  
The c-Fos antibody (sc-52; Santa Cruz Biotechnology,  
Santa Cruz,  CA,  USA) is a rabbit polyclonal anti-
body raised against a peptide mapping at the amino 
terminus of human c-Fos p62.  Sections were then 
rinsed and incubated with a secondary antibody (bioti-
nylated goat anti-rabbit IgG [1 : 400 dilution; Vector 
Laboratories,  Burlingame,  CA,  USA] in PBS with 
0.3ｵ Triton X-100) for 75min at room temperature.  
After rinsing,  sections were transferred into PBS 
containing 0.4ｵ avidin-biotinylated horseradish per-
oxidase complex (Vector Laboratories) for a further 
75min.  After successive washes in PBS and 0.2M 
sodium acetate buﬀer (pH6.0),  the reaction product 
was visualized using a glucose oxidase-diaminobenzi-
dine-nickel method [14].  The reaction was terminated 
by washing the sections in sodium acetate buﬀer.  
Thereafter,  the sections were mounted onto chrome/
alum/gelatin-coated slides from 0.05M PBS.  After 
air-drying,  sections were counterstained with neutral 
red,  dehydrated through a graded alcohol series,  
cleared in xylene,  and cover-slipped.  Cells from the 
motor 1 (M1),  motor 2 (M2),  cingulate 1 (Cg1),  pre-
limbic (PrL) and infralimbic (IL) areas of the prefron-
tal cortex and the CA1,  CA2,  CA3 and the dentate 
gyrus of the hippocampus (Fig.  1) were examined 
under a magniﬁcation of×200.  Counting of positive 
cells was carried out bilaterally on a minimum of three 
representative sections (400µm×400µm) per region 
in each rat.  These counts were averaged into a single 
score for each region of each rat,  and the group mean 
± S.E.M calculated.
　 Experimental procedures. ECS was adminis-
tered for 7 consecutive days.  The Y-maze and open-
ﬁeld tests were carried out 24h after the last admin-
istration of ECS.  Valproate (250-500mg/kg,  i.p.) or 
saline (i.p.) was injected 30min before the daily 
administration of ECS or sham administration for 7 
days.  Levels of BDNF and c-Fos protein were mea-
sured 24h after the last administration of ECS.
　 Statistical analyses. The prevalence of tonic-
clonic seizures was assessed for signiﬁcance by the 
chi-squared test for independence.  If more than 2 
groups were compared,  the signiﬁcance of the diﬀer-
ences among groups was evaluated through a one-way 
analysis of variance (ANOVA).  Two-way ANOVA,  
with ECS administration as the between-subjects fac-
tor and valproate treatment as the within-subject fac-
tor,  was used.  If signiﬁcant diﬀerences were obtained,  
post-hoc comparisons within logical sets of means were 
carried out using Bonferroniʼs test.  Signiﬁcance was 
deﬁned as p＜0.05.
Results
　 The Eﬀect of valproate on the prevalence of 
ECS-induced tonic-clonic seizures. The eﬀect 
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of valproate (250-500mg/kg) on the prevalence of 
ECS-induced tonic-clonic seizures in rats is shown in 
Fig.  2.  Tonic-clonic seizures occurred in all rats of 
the saline-treated group that received ECS.  
Pretreatment with valproate (250-500mg/kg) 
decreased the prevalence of tonic-clonic seizures in a 
dose-dependent manner; 500mg/kg of valproate com-
pletely abolished ECS-induced seizures (p＜0.001,  
chi-squared test).
　 Eﬀect of repeated administration of valproate 
on spontaneous alternation behavior. The 
eﬀect of repeated administration of valproate (350-
500mg/kg) on spontaneous alternation behavior in 
rats is shown in Fig.  3.  A one-way ANOVA revealed 
that 7-day administration of valproate (500mg/kg) 
had a signiﬁcant eﬀect of increasing the total number 
of arm entries [F(3, 27)＝4.188,  p＜0.05],  but had no 
signiﬁcant eﬀect on spontaneous alternation behavior 
[F(3, 27)＝0.756,  p＞0.05] or locomotor activity 
[F(3, 27)＝0.653,  p＞0.05].  The post-hoc compari-
son using Bonferroniʼs test revealed that 500mg/kg of 
valproate signiﬁcantly increased the number of total 
arm entries in comparison with those in saline-treated 
control rats (p＜0.05).
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Fig. 1　 Drawings of representative sections used for the quantiﬁcation of expression of c-fos protein.  Nine areas of the brain were 
selected for counting c-fos protein expression: the M1 (1),  M2 (2),  Cg1 (3),  PrL (4) and IL (5) of the prefrontal cortex,  and the CA1 (6),  
CA2 (7),  CA3 (8) and dentate gyrus (9) of the hippocampus.  The numbers above each brain section represent the distance (mm) from the 
bregma as detailed in the Atlas of Paxinos and Watson (2007).
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Fig. 2　 Eﬀect of valproate on ECS-induced tonic-clonic seizures 
in rats. Valproate (250-500mg/kg, i.p.) was injected 30 min before 
ECS administration.  The columns represent the percentage of 
tonic-clonic seizures (n＝8-9); ＊p＜0.05,  ＊＊p＜0.01,  ＊＊＊p＜0.001 
in comparison with ECS-administered saline-treated rats (chi-
squared test).
　Seven-day administrations of ECS produced a sig-
nificant impairment in spontaneous alternation 
[F(4, 30)＝5.451,  p＜0.01] and signiﬁcantly increased 
the total number of arm entries [F(4, 30)＝9.680,  p
＜0.001] and locomotor hyperactivity [F(4, 30)＝
5.881,  p＜0.01].  Daily pretreatment with valproate 
(350 and 400mg/kg) signiﬁcantly reversed the impair-
ment of spontaneous alternation behavior (p＜0.05).  
All dosages of valproate signiﬁcantly suppressed the 
increase in the total number of arm entries and loco-
motor hyperactivity (p＜0.05 or p＜0.01,  Fig.  4).  The 
eﬀect of low-dose valproate (250mg/kg) was also 
investigated.  ECS-induced impairment of spontaneous 
alternation was not reversed by daily pretreatment 
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Fig. 3　 Eﬀects of valproate on spontaneous alternation behavior in the Y-maze test and locomotor activity in the open-ﬁeld test.  Rats 
were injected with valproate (350-500mg/kg, i.p.) once daily for 7 days. The columns represent means ± S.E.M (n＝6-9). ＊p＜0.05 in 
comparison with saline-treated rats (one-way ANOVA followed by Bonferroniʼs test).
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Fig. 4　 Eﬀects of valproate on the impairment of spontaneous alternation behavior and locomotor hyperactivity induced by repeated 
administration of ECS in Rats.  Valproate (350-500mg/kg, i.p.) was injected 30 min before the daily administration of ECS for 7 days.  The 
columns represent means ± S.E.M. (n＝7).  ＊p＜0.05,  ＊＊p＜0.01 in comparison with sham-administered rats,  †p＜0.05,  ††p＜0.01 in 
comparison with repeated ECS-administered rats (one-way ANOVA followed by Bonferroniʼs test).
with 250mg/kg of valproate [sham group,  64.9±
4.8ｵ; ECS＋saline group,  50.6±5.3ｵ; ECS＋
valproate group,  60.5±3.1ｵ; n＝7-8; signiﬁcant 
diﬀerence (p＜0.05) between sham and ECS＋saline 
groups].  Similarly,  the pretreatment of 250mg/kg 
valproate had no signiﬁcant eﬀect on the locomotor 
hyperactivity induced by ECS [sham group,  106.7±
5.8; ECS＋saline group,  155.0±21.3; ECS＋val-
proate group,  132.0±8.1; n＝7-8; signiﬁcant diﬀer-
ence (p＜0.05) between sham and ECS＋saline 
groups].
　 Eﬀects of repeated administration of ECS 
and valproate on levels of BDNF protein. The 
eﬀects of repeated administration of ECS and val-
proate (400mg/kg,  i.p.) on BDNF protein levels in rat 
brains are shown in Fig.  5.  Two-way ANOVA 
revealed a signiﬁcant eﬀect of ECS administration 
[hippocampus,  F(1, 36)＝62.264,  p＜0.001; prefron-
tal cortex,  F(1, 36)＝18.046,  p＜0.001] but no sig-
niﬁcant eﬀect of valproate treatment [hippocampus,  
F(1, 36)＝1.034,  NS; prefrontal cortex,  F(1, 36)＝
3.650,  NS].  Bonferroniʼs test revealed that repeated 
administration of ECS signiﬁcantly increased the 
BDNF protein levels of the prefrontal cortex (p＜
0.05) and hippocampus (p＜0.01).  Daily pretreatment 
with valproate had no signiﬁcant eﬀect on the 
increases in BDNF protein levels.
　 Eﬀects of repeated administration of ECS 
and valproate on levels of c-Fos protein. The 
eﬀects of repeated administration of ECS and val-
proate (400mg/kg,  i.p.) on c-Fos protein levels in rat 
brains are shown in Table 1.  Repeated administration 
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Table 1　 Levels of c-Fos protein after the administration of ECS or valproate in rat brains
Prefrontal Cortex Hippocampus
M1 M2 Cg1 PrL IL CA1 CA2 CA3 Dentate Gyrus
Sham 8.5±3.8 18.8±6.4 58.3±7.0 40.0±6.4 58.1±8.6 7.5±1.2 10.3±2.1 4.3±1.1 10.2±1.1
ECS 5.0±3.1 16.3±4.6 45.6±7.8 64.3±3.8 61.8±5.6 9.0±1.2 9.9±1.7 6.4±0.8 2.2±0.4＊＊
Valproate 5.0±2.6 17.0±4.2 40.8±9.5 45.7±6.1 95.8±8.3 5.3±1.6 3.4±1.7 2.6±1.0 21.8±4.3＊＊,††
ECS＋Valproate 9.2±1.6 34.0±3.0＊,† 80.6±8.1†,＃ 107.3±7.6＊＊,††,＃＃ 89.4±8.3 7.6±1.5 8.5±2.4 8.4±1.6＊,＃＃ 2.9±0.5＊＊,＃＃
ECS was administered once daily for 7 d.
Valproate (400mg/kg, i.p.) was injected 30 min before the daily ECS- or sham-administration rats for 7 d.
Values represent the mean ± S.E.M. (n＝4-8 rats in each group).
＊p＜0.05,  ＊＊p＜0.01 in comparison with sham-administered rats,  
†p＜0.05,  ††p＜0.01 in comparison with repeated ECS-administered rats,  
＃p＜0.05,  ＃＃p＜0.01 in comparison with repeated VPA-administered rats (two-way ANOVA followed by Bonferroniʼs test).
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Fig. 5　 Eﬀects of valproate on the BDNF protein level in the hippocampus and the prefrontal cortex in rats.  Valproate (400mg/kg, i.p.) 
was injected 30 min before the daily administration of ECS for 7 days.  The columns represent means ± S.E.M (n＝10).  ＊p＜0.05,  ＊＊p＜
0.01 in comparison with sham-administered rats (two-way ANOVA followed by Bonferroniʼs test).
of ECS caused a speciﬁc reduction in the c-Fos pro-
tein level in the dentate gyrus of the hippocampus 
compared with the sham group (p＜0.01,  Bonferroniʼs 
test).  Repeated administration of valproate produced 
a speciﬁc increase in the c-Fos protein level in the 
dentate gyrus of the hippocampus (p＜0.01,  Bonferroniʼs 
test).  Daily pretreatment with valproate had no sig-
niﬁcant eﬀect on the decrease in c-Fos protein level 
induced by ECS.  In the prefrontal cortex,  valproate
＋ECS signiﬁcantly increased the c-Fos protein lev-
els of M2,  Cg1 and PrL compared with the ECS 
group (p＜0.05 or p＜0.01,  Bonferroniʼs test).
Discussion
　 Our previous study indicated that repeated admin-
istration of ECS produced an impairment of spontane-
ous alternation behavior in a Y-maze test and the 
development of locomotor hyperactivity in an open-
ﬁeld test [3].  In the present study,  we investigated in 
detail the inhibitory eﬀect of valproate on these 
behavioral changes.  In studies using naïve rats,  val-
proate (350 and 400mg/kg) had no eﬀect on spontane-
ous alternation behavior and locomotor activity,  but 
500mg/kg valproate slightly impaired spontaneous 
alternation behavior and signiﬁcantly (p＜0.05) 
increased the total number of arm entries in the 
Y-maze test.  These results supported the notion that 
high doses of valproate produced behavioral impair-
ments,  in accordance with previous studies [15-18].
　 Valproate (250-500mg/kg) dose-dependently inhib-
ited ECS-induced tonic-clonic seizures,  and 500mg/
kg valproate fully prevented seizures.  Inhibition of 
ECS-induced seizures by pretreatment with valproate 
(350-500mg/kg) signiﬁcantly suppressed locomotor 
hyperactivity.  Moreover,  impairment of spontaneous 
alternation was improved by pretreatment with val-
proate (350 and 400mg/kg).  However,  500mg/kg of 
valproate had no signiﬁcant eﬀect on the impairment 
in spontaneous alternation,  suggesting that 500mg/kg 
valproate may be an overdose.  Based on these results,  
the minimum dose of valproate (400mg/kg) was used 
to examine the mechanism of valproate against ECS-
induced behavioral impairments.
　 Several studies have demonstrated that BDNF has 
important and varying roles in the development of 
learning or kindling.  BDNF mutant mice had impaired 
spatial learning in the water maze test [20],  and 
intraventricular infusion of an anti-BDNF antibody 
resulted in impairment of water-maze learning in rats 
[21].  Increases in the expression of BDNF have been 
reported in various experimental models of seizures 
such as pentylenetetrazole- or ﬂurothyl-induced kin-
dling [22-24] and recurrent seizures induced by 
ECS [5,  9].  However,  its role remains controver-
sial.  Several data have suggested that BDNF may 
facilitate epileptogenesis [25,  26],  while other stud-
ies support an inhibitory function [27].  Reibel et al.,  
reported that repeated intrahippocampal infusion of 
BDNF delays kindling epileptogenesis in rats [28].  
On the other hand,  electroconvulsive therapy and 
nonconvulsive electric-stimulation therapy (transcra-
nial magnetic stimulation) are eﬀective for depression,  
and these treatments have been reported to increase 
BDNF levels in the rat brain [29].  In the present 
study,  repeated ECS-induced seizures signiﬁcantly 
increased BDNF protein levels in the hippocampus 
and prefrontal cortex.  Daily pretreatment with val-
proate inhibited the ECS-induced seizures and sup-
pressed the impaired spontaneous alternation behavior 
induced by repeated administration of ECS [3],  but 
valproate had no eﬀect on the increase in BDNF pro-
tein levels.  These ﬁndings suggest that electrical 
stimulation (but not seizure) increases BDNF protein 
levels,  and that the increased BDNF levels may not be 
involved in repeated ECS-induced behavioral impair-
ments in rats.
　 Previous studies have reported that 7-day pre-
treatment with valproate increased the hippocampal 
activator protein 1 (AP-1) activity in kainic acid-
induced epilepsy rats [30].  Chronic treatment of 
valproate for 7 days increased c-Fos and AP-1 DNA 
binding activity in human neuroblastoma SH-SY5Y 
cells [31].  AP-1 forms a homodimeric or heterodi-
meric complex with 2 transcription factor families,  
c-Fos and c-Jun.  Previous studies suggested that 
valproate may increase AP-1 DNA binding activity via 
protein kinase C (PKC)-mitogen activated protein 
kinase (MAPK) pathways [32] and promote neurogen-
esis [33].  In addition,  valproate stimulates the pro-
liferation of rat neural progenitor cells and increases 
neuronal diﬀerentiation associated with GABA 
expression [34,  35].  In the present study,  a signiﬁ-
cant increase in the c-Fos protein level (a maker of 
neuronal activity) was shown in only the dentate gyrus 
of the hippocampus.  Taken together,  these results 
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suggest that the neurogenesis of valproate may be 
related with these phenomena.  However,  further 
investigation is required to evaluate the observation of 
neuronal proliferation by the bromodeoxyuridine 
(BrdU) labeling technique.
　 Lukoyanov et al.  (2004) reported that six ECS 
administrations caused loss of cells in the hilus of the 
dentate gyrus [36].  In addition,  ECS seizures pro-
duced atrophic changes in the dendritic arbors of 
dentate gyrus granule cells [37].  These ﬁndings sug-
gest that repeated ECS-induced seizures can produce 
morphological changes in the brain.  In the present 
study,  the c-Fos protein level decreased in the dentate 
gyrus of the hippocampus after repeated administra-
tions of ECS for 7 days.  In addition,  inhibition of 
ECS-induced seizures by pretreatment with valproate 
did not produce a signiﬁcant ameliorating eﬀect on the 
c-Fos level of the hippocampal dentate gyrus.  On the 
other hand,  valproate＋ECS signiﬁcantly increased 
the c-Fos protein levels of M2,  Cg1 and PrL of the 
prefrontal cortex compared with the ECS group.  The 
prefrontal cortex has been shown to have an important 
role in learning and memory [8].  Studies reported 
that lesions of PrL-IL impair the visual attention 
performance in the 3-choice serial reaction time task 
[38],  and that Cg-lesioned rats disrupt the spatial 
alternation performance [39].  These results suggest 
that the inhibitory eﬀect of valproate on repeated 
ECS-induced impairment of spontaneous alternation 
behavior may be linked to the prefrontal cortex.  Our 
recent study showed that a serotonin-dopamine recep-
tor antagonist,  risperidone,  improved the impairment 
of spontaneous alternation and the locomotor hyperac-
tivity induced by ECS [40].  Therefore,  further 
studies will be necessary to clarify the precise mecha-
nisms of dopaminergic and serotonergic neurotrans-
missions in the prefrontal cortex.
　 In conclusion,  the results of the current study 
indicate that pretreatment with valproate improved 
repeated ECS-induced impairment of spontaneous 
alternation behavior,  and that the prefrontal cortex 
may be associated with these phenomena.
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